Regeneron, Sanofi talk up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII
A busy clinical team at Regeneron $REGN and Sanofi $SNY has outlined another segment on the allergic inflammatory map that they plan to build their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
